NovaBay Pharmaceuticals Inc (NBY)
2.17
0.00 (0.00%)
USD |
NYAM |
Jul 05, 15:57
NovaBay Pharmaceuticals SG&A Expense (Annual): 12.83M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.83M |
| December 31, 2022 | 15.29M |
| December 31, 2021 | 15.33M |
| December 31, 2020 | 12.10M |
| December 31, 2019 | 14.08M |
| December 31, 2018 | 18.62M |
| December 31, 2017 | 22.35M |
| December 31, 2016 | 19.04M |
| December 31, 2015 | 18.53M |
| December 31, 2014 | 7.989M |
| Date | Value |
|---|---|
| December 31, 2013 | 6.34M |
| December 31, 2012 | 5.973M |
| December 31, 2011 | 5.429M |
| December 31, 2010 | 5.654M |
| December 31, 2009 | 5.607M |
| December 31, 2008 | 5.636M |
| December 31, 2007 | 4.368M |
| December 31, 2006 | 2.972M |
| December 31, 2005 | 1.617M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
12.10M
Minimum
2020
15.33M
Maximum
2021
13.93M
Average
14.08M
Median
2019
SG&A Expense (Annual) Benchmarks
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 19.02M |
| Theriva Biologics Inc | 7.12M |
| Oragenics Inc | 5.452M |
| Nanoviricides Inc | 2.551M |